Presentation is loading. Please wait.

Presentation is loading. Please wait.

Figure 1 Flowchart illustrating numbers of cases evaluated at each stage of study. SADS, sudden arrhythmic death ... Figure 1 Flowchart illustrating numbers.

Published byLambert Barrett Modified over 5 years ago

Similar presentations

Presentation on theme: "Figure 1 Flowchart illustrating numbers of cases evaluated at each stage of study. SADS, sudden arrhythmic death ... Figure 1 Flowchart illustrating numbers."— Presentation transcript:

1 Figure 1 Flowchart illustrating numbers of cases evaluated at each stage of study. SADS, sudden arrhythmic death ... Figure 1 Flowchart illustrating numbers of cases evaluated at each stage of study. SADS, sudden arrhythmic death syndrome; SCD, sudden cardiac death; SUD, sudden unexplained death; SUDEP, sudden unexplained death in epilepsy; RMH, Royal Melbourne Hospital; VIFM, Victorian Institute of Forensic Medicine. Key: *Includes five cases without coronial permission to refer. Unless provided in the caption above, the following copyright applies to the content of this slide: Published on behalf of the European Society of Cardiology. All rights reserved. © The Author(s) For permissions, please article is published and distributed under the terms of the Oxford University Press, Standard Journals Publication Model ( European Heart Journal, Volume 40, Issue 10, 30 October 2018, Pages 831–838, The content of this slide may be subject to copyright: please see the slide notes for details.

2 Unless provided in the caption above, the following copyright applies to the content of this slide: Published on behalf of the European Society of Cardiology. All rights reserved. © The Author(s) For permissions, please article is published and distributed under the terms of the Oxford University Press, Standard Journals Publication Model ( European Heart Journal, Volume 40, Issue 10, 30 October 2018, Pages 831–838, The content of this slide may be subject to copyright: please see the slide notes for details.

3 Figure 2 Uncertain autopsy findings identified following unexplained sudden cardiac death and associated cardiogenetic ... Figure 2 Uncertain autopsy findings identified following unexplained sudden cardiac death and associated cardiogenetic clinical phenotypes identified in blood relatives. BrS, Brugada syndrome; DCM, dilated cardiomyopathy; FMD, fibromuscular dysplasia of coronary/AV nodal arteries; LV, left ventricular; LQT, long QT syndrome; SUD, sudden unexplained death; RV, right ventricular. Unless provided in the caption above, the following copyright applies to the content of this slide: Published on behalf of the European Society of Cardiology. All rights reserved. © The Author(s) For permissions, please article is published and distributed under the terms of the Oxford University Press, Standard Journals Publication Model ( European Heart Journal, Volume 40, Issue 10, 30 October 2018, Pages 831–838, The content of this slide may be subject to copyright: please see the slide notes for details.

4 Figure 3 Histogram of number of uncertain cardiac autopsy findings per case identified in unexplained sudden cardiac ... Figure 3 Histogram of number of uncertain cardiac autopsy findings per case identified in unexplained sudden cardiac death (SCD, blue) probands and non-cardiac premature deaths (control, green). Significantly more unexplained SCD cases with ≥1 uncertain finding (P < 0.001). Unless provided in the caption above, the following copyright applies to the content of this slide: Published on behalf of the European Society of Cardiology. All rights reserved. © The Author(s) For permissions, please article is published and distributed under the terms of the Oxford University Press, Standard Journals Publication Model ( European Heart Journal, Volume 40, Issue 10, 30 October 2018, Pages 831–838, The content of this slide may be subject to copyright: please see the slide notes for details.

5 Figure 4 Diagnostic yield of cardiogenetic disease following cardiological evaluation of blood relatives of ... Figure 4 Diagnostic yield of cardiogenetic disease following cardiological evaluation of blood relatives of unexplained sudden cardiac death probands with normal (left; true SADS) and non-diagnostic (right; uncertain SUD) cardiac autopsy findings. No significant difference between proportions identified with cardiogenetic disease (P = 0.34). BrS, Brugada syndrome; DCM, dilated cardiomyopathy; LQT, long QT syndrome; PCCD, progressive cardiac conduction disease; SADS, sudden arrhythmic death syndrome; SQT, short QT syndrome; SUD, sudden unexplained death. Unless provided in the caption above, the following copyright applies to the content of this slide: Published on behalf of the European Society of Cardiology. All rights reserved. © The Author(s) For permissions, please article is published and distributed under the terms of the Oxford University Press, Standard Journals Publication Model ( European Heart Journal, Volume 40, Issue 10, 30 October 2018, Pages 831–838, The content of this slide may be subject to copyright: please see the slide notes for details.

6 Figure 5 Examples of uncertain histological findings identified in sudden unexplained death (SUD) cases (haematoxylin ... Figure 5 Examples of uncertain histological findings identified in sudden unexplained death (SUD) cases (haematoxylin and eosin stained sections): (A) myocardial hypertrophy and pericellular fibrosis in the septum centrally (×10 magnification), identified in a family with no definite cardiogenetic disease; (B) fat infiltration and replacement fibrosis in the right ventricle (×2 magnification) insufficient to meet minor criteria for arrhythmogenic cardiomyopathy diagnosis, identified in a family with Brugada syndrome; (C) moderate left anterior descending coronary artery stenosis (assessed as 60% stenosis in a collapsed artery that was macroscopically patent prior to histological slide creation) due to soft plaque (main image ×2 magnification) in a 35-year-old, also associated with a distal intramyocardial course (inset image ×10 magnification), identified in a family with dilated cardiomyopathy; (D) myxoid mitral valve degeneration (main image ×2 and inset image ×10 magnification), identified in a family with long QT syndrome. Unless provided in the caption above, the following copyright applies to the content of this slide: Published on behalf of the European Society of Cardiology. All rights reserved. © The Author(s) For permissions, please article is published and distributed under the terms of the Oxford University Press, Standard Journals Publication Model ( European Heart Journal, Volume 40, Issue 10, 30 October 2018, Pages 831–838, The content of this slide may be subject to copyright: please see the slide notes for details.

7 Take home figure Risk factors for unexplained sudden cardiac death: cardiogenetic diseases and uncertain cardiac histological ... Take home figure Risk factors for unexplained sudden cardiac death: cardiogenetic diseases and uncertain cardiac histological characteristics are both implicated. Unless provided in the caption above, the following copyright applies to the content of this slide: Published on behalf of the European Society of Cardiology. All rights reserved. © The Author(s) For permissions, please article is published and distributed under the terms of the Oxford University Press, Standard Journals Publication Model ( European Heart Journal, Volume 40, Issue 10, 30 October 2018, Pages 831–838, The content of this slide may be subject to copyright: please see the slide notes for details.

Download ppt "Figure 1 Flowchart illustrating numbers of cases evaluated at each stage of study. SADS, sudden arrhythmic death ... Figure 1 Flowchart illustrating numbers."

Similar presentations

Figure 1 Rates of complications and mortality during index admission for atrial fibrillation ablation for the overall ... Figure 1 Rates of complications.

Figure 1 Rates of complications and mortality during index admission for atrial fibrillation ablation for the overall ... Figure 1 Rates of complications.
Figure 1 Periprocedural myonecrosis and myocardial infarction after left main coronary artery revascularization with ... Figure 1 Periprocedural myonecrosis.

Figure 1 Periprocedural myonecrosis and myocardial infarction after left main coronary artery revascularization with ... Figure 1 Periprocedural myonecrosis.
Figure 1 Subject phenotypes and most common genotype in subjects enrolled in THAOS in continental Western Europe. Data ... Figure 1 Subject phenotypes.

Figure 1 Subject phenotypes and most common genotype in subjects enrolled in THAOS in continental Western Europe. Data ... Figure 1 Subject phenotypes.
Figure 1 Study flow diagram and definition of clinical response

Figure 1 Study flow diagram and definition of clinical response
Unless provided in the caption above, the following copyright applies to the content of this slide: © 2019 European Society of Cardiology and British Pharmacological.

Unless provided in the caption above, the following copyright applies to the content of this slide: © 2019 European Society of Cardiology and British Pharmacological.
Unless provided in the caption above, the following copyright applies to the content of this slide: Published by Oxford University Press on behalf of the.

Unless provided in the caption above, the following copyright applies to the content of this slide: Published by Oxford University Press on behalf of the.
Figure 1 Data-selection process

Figure 1 Data-selection process
Figure 1 Flow diagram detailing the systematic review process.

Figure 1 Flow diagram detailing the systematic review process.
Figure 1 Multivariable-adjusted predictors of PAC

Figure 1 Multivariable-adjusted predictors of PAC
Unless provided in the caption above, the following copyright applies to the content of this slide: Published on behalf of the European Society of Cardiology.

Unless provided in the caption above, the following copyright applies to the content of this slide: Published on behalf of the European Society of Cardiology.
Unless provided in the caption above, the following copyright applies to the content of this slide: Published on behalf of the European Society of Cardiology.

Unless provided in the caption above, the following copyright applies to the content of this slide: Published on behalf of the European Society of Cardiology.
Figure 1 Unadjusted Kaplan–Meier curves for all-cause mortality in the transcatheter mitral valve repair and ... Figure 1 Unadjusted Kaplan–Meier curves.

Figure 1 Unadjusted Kaplan–Meier curves for all-cause mortality in the transcatheter mitral valve repair and ... Figure 1 Unadjusted Kaplan–Meier curves.
Figure 1 Mechanism of mortality benefit associated with radial access

Figure 1 Mechanism of mortality benefit associated with radial access
Unless provided in the caption above, the following copyright applies to the content of this slide: Published on behalf of the European Society of Cardiology.

Unless provided in the caption above, the following copyright applies to the content of this slide: Published on behalf of the European Society of Cardiology.
Figure 1 Number of percutaneous coronary interventions (PCI) in mainland China, 2017 (total 753 142). Data from China ... Figure 1 Number of percutaneous.

Figure 1 Number of percutaneous coronary interventions (PCI) in mainland China, 2017 (total 753 142). Data from China ... Figure 1 Number of percutaneous.
Figure 1 Phases of the research. Author’s own work.

Figure 1 Phases of the research. Author’s own work.
Unless provided in the caption above, the following copyright applies to the content of this slide: Published by Oxford University Press on behalf of the.

Unless provided in the caption above, the following copyright applies to the content of this slide: Published by Oxford University Press on behalf of the.
Figure 1 The Kaplan–Meier curves of time to death post first hospitalization. hosp, hospitalization. Unless provided in the caption above, the following.

Figure 1 The Kaplan–Meier curves of time to death post first hospitalization. hosp, hospitalization. Unless provided in the caption above, the following.
AHA: American Heart Association; ALT: ...

AHA: American Heart Association; ALT: ...
Figure 1. Serum ceftazidime concentrations following intravenous administration. Unless provided in the caption above, the following copyright applies.

Figure 1. Serum ceftazidime concentrations following intravenous administration. Unless provided in the caption above, the following copyright applies.

Similar presentations

Ads by Google